

Blast count prognostic for CML presenting in advanced phase

September 26 2019



(HealthDay)—Blast count seems to be the main prognostic count for

patients with chronic myeloid leukemia (CML) presenting in an advanced phase, according to a study published online Aug. 27 in the *American Journal of Hematology*.

Michael Lauseker, Ph.D., from Ludwig-Maximilians-Universität München in Germany, and colleagues examined prognostic factors for a cohort of 283 patients diagnosed in the advanced phase of CML. Nearly all of the patients received tyrosine kinase inhibitor treatment.

The researchers found that median survival was 8.2 years in the heterogeneous cohort. The hazard ratio for mortality was 1.32 (95 percent confidence interval [CI], 0.7 to 2.6) when comparing patients with >30 percent versus 20 to 29 percent blasts, respectively. Significantly higher risk for [mortality](#) was seen for patients with 20 to 29 percent versus

Citation: Blast count prognostic for CML presenting in advanced phase (2019, September 26) retrieved 20 February 2023 from <https://medicalxpress.com/news/2019-09-blast-prognostic-cml-advanced-phase.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--